Tigermed schedules board meeting to review H1 interim results, consider interim dividendPUBT·2 days ago, 04:34 AM03347+5.63%300347+7.22%
Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Receives a Buy from CitiTip Ranks·Jul 22 at 07:27 PM03347+5.63%300347+7.22%
UBS: CN CRO Sees Solid Revenue Growth in 1H; WUXI APPTEC Top PickAASTOCKS News·Jul 14 at 02:56 AM02269+3.63%02359+2.28%
UBS' Investment Ratings and TPs on CRO Stocks (Table)AASTOCKS News·Jul 14 at 02:00 AM300759+5.06%02268+3.16%
